Main Article Content


Foot infection is a common and serious problem in people with diabetes, which require proper management (diagnostic and therapeutic approaches) that can be cured. Empiric antibiotic regimen should be based on clinical data and bacteria pattern that are available, but definitive therapy should be based on the results of the infected tissue culture. The selection of initial antibiotic therapy was difficult and unwise use can lead to antibiotic-resistant. Evaluation is needed for using antibiotics to benefit wisely. The aim of this research is to analyzed the pattern of bacteria in diabetic foot and to its sensitivity test to antibiotics, analyze empiric antibiotics that can be recommended, and analyzed the use of antibiotics by Gyssen method. Data was analyzed with observational studies (descriptive non-experimental), retrospectively and prospectively in patients diabetic foot infection that met inclusion criteria. Retrospective data are used to analyzed bacteria pattern and its sensitivity test, while prospective data are used to evaluated the use of antibiotics based on bacteria pattern, during the period of late March-early August 2015 at Mardi Waluyo Hospital. Evaluation was conducted by Gyssen method. The results, retrospective data samples obtained 30 infection bacteria during August 2014-March 2015. The prevalence of gram-negative bacteria as 53.33% with most types of bacteria E.coli and Klebsiella oxytoca (13.33%), and gram-positive bacteria as 46.67% with the highest bacteria are Staphylococcus spp. and Streptococcus spp. From the prospective data in inclusion criteria, 13 patients with the highest prevalence of gram-negative bacteria are Klebsiella oxytoca (28.57%), and most gram-positive Staphylococcus auerus (35.71%). While the qualitative analysis of antibiotic use was conducted on 50 types of antibiotics. The results of the qualitative analysis using Gyssens method obtained category as 62%, 2%, 14%, 2B category as 26%, 3A category as 10%, 4A category 52%, 4B category as 6%, 4C category as 8% and there are no use of antibiotics in the category V and VI. Conclusions, Gyessen method can show that the use of antibiotics in diabetic foot patients in Mardi Waluyo hospital is dominated by inaccuracy in choice of antibiotic, and inaccuracies in the interval antibiotics.


bacteria patterns antibiotics diabetic foot infections Gyssens method

Article Details

How to Cite
Fadlilah, U., Hasmono, D., Wibisono, Y. A., & Melinda, M. (2017). ANTIBIOGRAM STUDY AND ANTIBIOTIC USE EVALUATION USING GYSSEN METHOD IN PATIENTS WITH DIABETIC FOOT. Folia Medica Indonesiana, 52(3), 198–208.


  1. Adibhatla RM, Hatcher JF, Larsen EC, Chen X, Sun D, Tsao FH (2006). CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke. Journal of Biological Chemistry 281, 6718–6725
  2. Adibhatla R, Hatcher J, Dempsey R (2001). Effect of citicoline on phospholipid and glutathione levels in transient cerebral ischemia. Stroke 32, 2376-2381
  3. Archer GL and Polk RE (2010). Treatment and prophylaxis of bacterial infections. In: Kasper DL, and Fauci AS (eds). Harrison's Infectious Disease, New York, McGraw-Hill Comp, p 354-374
  4. Bader M (2008). Diabetic Foot Infection. American Family Physician 78, 71-79
  5. Castellanos M, Sobrino T, Castillo J (2006). Evolving paradigms for neuroprotection: molecular identification of ischemic penumbra. Cerebrovasc Dis 21, 71-79
  6. Chahine EB, Harris S, Williams R (2013). Diabetic foot infection: an update on treatment. US Pharm 38, 23-26
  7. Dávalos A, Alvarez Sabí­n J, Castillo J, Dí­ez Tejedor E, Ferro J, Martí­nez Vila E, et al (2012). Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicenter, placebo-controlled study (ICTUS Trial). The Lancet 380, 349-357
  8. Farooqui A, Horrocks L, Farooqui T (2005). Glycerophospholipids in brain: their metabolism, incorporation to membranes, functions, and involvement in neurological disorders. Chem Phys Lipids 10, 6718–6725
  9. Fauci AS and Kasper DL (2010). Harrison's Infectiuous Diseases, New York, McGraw Hill Comp
  10. Frier BM and Fisher M (2007). Diabetes mellitus. In: Boon NA, Colledge NR, Walker BR, Hunter J (eds). Davidson's Principles and Practice of Medicine, 20th ed, London, Churchill Livingstone
  11. Frykberg RG, Zgonis T, Armstrong DG, Driver VR, Giurini GM, Kravitz SR, Lansman AS, Lavery LA, Moore JC, Schuberth JM, Wukich DK, Andersen C, Vanore JV (2006). Diabetic foot disorders: a clinical practice guideline (2006 revision). The Journal of Foot & Ankle Surgery 45, S2-S66
  12. Gadepalli R, Dhawan B, Sreenivas V, Kapil A, Ammini AC, Chaudhry R (2006). A clinico-microbiological study of diabetic foot ulcers in an Indian tertiary care hospital. Diabetes Care 29, 1727-1732
  13. Gyssens IC (2005). Audits for monitoring the quality of antimicrobial prescriptions. In: Gould IM and van der Meer JWM (eds). Antibiotic Policies: Theory and Practice, New York, Kluwer Academic/Plenum Publishers
  14. Hindler JF and Stelling J (2007). Analysis and presentation of cumulative antibiograms: a new consensus guideline from the clinical and laboratory standards institute. Clin Infect Dis 44, 867–873
  15. Hurtado O, Moro MA, Cárdenas A, Sánchez V, Fernández-Tomé P, Leza JC, Lorenzo R, Dávalos A, Castillo J (2005). Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiology of Disease 18, 336-345
  16. Jí¸rgensen MB and Diemer NH (1982). Selective neuron loss after cerebral ischemia in the rat: possible role of transmitter glutamate. Acta Neurologica Scandinavica 66, 536-546
  17. Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R (2002). CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Neuropharmacology 42, 846-854
  18. Lacy CF, Armstrong LL, Lance LL, Goldman MP (2009). Drug Information Handbook with International Trade Names Index, 18th ed, Ohio, Lexi-comp
  19. Lampiris HW and Maddix DS (2007). Clinical use of antimicrobial agents. In: Katzung BG (ed). Basic and Clinical Pharmacology, 10th ed, New York, McGraw-Hill Comp, p 827-841
  20. Levin ME (2001). Pathogenesis and general management of foot lesions in the diabetic patiens. In: Levin ME (ed). The Diabetic Foot, 6th ed, St Louis, Mosby
  21. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS (2012). 2012 Infectiuous diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clinical Infectiuous Diseases 54, e132-e173
  22. Lipsky BA (2004). Medical treatment of diabetic foot infections. Clinical Infectious Diseases 39, S102-S114
  23. Lo E, Dalkara T, Moskowitz M (2003). Mechanisms, challenges an opportunities in stroke. Nat Rev Neurosci 4, 399-414
  24. Martinet M, Fonlupt P, Pacheco H (1979). Effects of cytidine-5' diphosphocholine on norepinephrine, dopamine and serotonin synthesis in various regions of the rat brain. Archives International de Pharmacodynamie et de Therapie 239, 52-61
  25. Martynov MY, Boiko AN, Kamchatnov PR, Kabanov AA, Yasamanova AN, Shchukin IA, Kolesnikova TI, Chubykin VI, Glukhareva AP, Gusev EI (2013). Neuroprotective therapy with citicoline (ceraxon) in patients with ischemic stroke. Neuroscience and Behavioral Physiology 43, 706-711
  26. Overgaard K (2014). The effects of citicoline on acute ischemic stroke: a review. Journal of Stroke and Cerebrovascular Diseases 23, 1764-1769
  27. Purba JM (2011). Biomolekuler stroke. In: Misbach J (ed). Stroke: Aspek Diagnostik, Patofisiologi, Manajemen, Jakarta, Penerbit Fakultas Kedokteran Universitas Indonesia, p 41-56
  28. Richard C and Schauss GA (2004). Therapeutic applications of citicoline for stroke and cognitive dysfunction in the elderly: a review of the literature. Alternative Medical Review 9, 17-31
  29. Richard,J.K,, New Insights in Diabetic Foot Infection, Guideline for Clinical Practice, World Journal of Diabetes, 2011 feb 15; 2(2): 24-32
  30. Riyanto B (2007). Infeksi pada kaki diabetik. In: Darmono et al (eds). Naskah Lengkap Diabetes Mellitus Ditinjau dari Berbagai Aspek Penyakit dalam dalam rangka Purna Tugas Prof Dr.dr.RJ Djokomoeljanto, Semarang, Badan Penerbit Universitas Diponegoro, p 15-30
  31. Ryan KJ and Ray CG (2004). An Introduction to Infectiuous Diseases, Sherris Medical Microbiology, 4th ed, New York, McGraw Hill Comp, p 261-271
  32. Sahota P and Savitz S (2011). Investigational therapies for ischemic stroke: neuroprotection and neurorecovery. Neurotherapeutics 8, 434-451
  33. Sapico FL (2007). Food ulcer in patients with diabetes mellitus. Journal of American Podiatric Medical Association 179
  34. Schena FP and Gesualdo L (2005). Pathogenetic mechanisms of diabetic nephropathy. Journal of the American Society of Nephrology 16, S30-S33
  35. Secades JJ (2002). CDP-choline: updated and review of its pharmacology and clinical use. Methods Find Exp Clin Pharmacol 24, 1-53
  36. Shaw JE, Sicree RA, Zimmet PZ (2010). Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Research and Clinical Practice 87, 4-14
  37. Cavalieri SJ, Harbeck RJ, McCarter YS, Ortez JH, Rankin ID, Sautter RL, Sharp SE, Spiegel CA (2005). Manual of Antimicrobial Susceptibility Testing, Washington DC, American Society for Microbiology
  38. Subekti I (2006). Neuropati diabetik. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S (eds). Buku Ajar Ilmu Penyakit Dalam, Jilid III, 4th ed, Jakarta, Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia
  39. Tambunan M (2004). Perawatan kaki diabetes. In: Soegondo S, et al (eds). Penatalaksanaan Diabetes Mellitus Terpadu: Sebagai Panduan Penatalaksanaan Diabetes Mellitus bagi Dokter maupun Edukator, Jakarta, Penerbit Fakultas Kedokteran Universitas Indonesia, p 293-298
  40. Tjokroprawiro A, Hendromartono, Sutjahjo A, Pranoto A, Murtiwi S, Soebagjo AS, Wibisono S (2007). Diabetes mellitus. In: Tjokroprawiro A, Setiawan PB, Santoso D, Soegiarto G (eds). Buku Ajar Ilmu Penyakit Dalam, Surabaya, Airlangga University Press, p 29-76
  41. Tortora GJ, Funke BR, Case CL (2010). Microbiology an Introduction, 10th edition, San Francisco, Pearson Education Inc, p 553-581
  42. Triplitt CL, Reasner CA, Isley WL (2008). Diabetes mellitus. In: Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM (eds). Pharmacotherapy: A Pathophisiologic Approach, 7th ed, New York, McGraw-Hill Comp
  43. Van der Meer JWM and Gyssens IC (2001). Quality of antimicrobial drug prescription in hospital. Clinical Microbiology and Infection 7, 12-15
  44. Wagner FW (1983). Algorithms of diabetic foot care. In: Levin ME and O'Neal LW (eds). The Diabetic Foot, 2nd ed, St Louis, Mosby
  45. Wahlgren N (1997). Neuroprotectants in late clinical development - a status report. Cerebrovascular Disease 7, 13-17
  46. Warach S, Creed Pettigrew L, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwinderski U, Gammans R (2000). Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Annals of Neurology 48, 713-722
  47. Waspadji S (2006). Kaki diabetes. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S (eds). Buku Ajar Ilmu Penyakit Dalam, Jilid III, 4th ed, Jakarta, Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia
  48. Waspadji S (2006). Komplikasi kronik diabetes: mekanisme terjadinya, diagnosis dan strategi pengelolaan. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S (eds). Buku Ajar Ilmu Penyakit Dalam, Jilid III, 4th ed, Jakarta, Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia
  49. WHO (2000). Prevention of Diabetes Mellitus. Technical Report Series 844. Geneva: World Health Organization
  50. Rathmann W and Giani (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 2568-2569
  51. WHO (2006). Neurological Disorder: Public Health Challenges. Geneva: World Health Organization
  52. Mardi Waluyo Hospital (2013). Profile Installation Medical Record of 2013. Blitar. Unpublished.

Most read articles by the same author(s)